Lead Plaintiff Deadline of March 16, 2026 in the Vistagen Therapeutics, Inc. (VTGN) Securities Class Action Announced by Holzer & Holzer, LLC

Core Viewpoint - A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. alleging false and misleading statements regarding the risks associated with the Phase 3 PALISADE-3 trial of fasedienol [1] Group 1: Lawsuit Details - The lawsuit claims that Vistagen failed to disclose material adverse facts related to the risks of failure in its clinical trial [1] - The class action is aimed at shareholders who purchased Vistagen shares between April 1, 2024, and December 16, 2025, and suffered significant losses [2] Group 2: Legal Representation - Shareholders are encouraged to contact Holzer & Holzer, LLC for legal representation, a firm recognized for its work in securities litigation [3] - The deadline for shareholders to be appointed as lead plaintiff in the case is March 16, 2026 [3]